Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy von d 'Arminio Monforte, A, Antinori, A, Cozzi-Lepri, A, Ceccherini-Silberstein, F, Castagna, A, Caputo, S.L, Mussini, C, De Luca, A, Madeddu, G, Cingolani, A, Tavelli, A, Taliani, G, Gori, A, Girardi, E, Puoti, M

Volltext

Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy von Torti, C., Prosperi, M., Motta, D., Digiambenedetto, S., Maggiolo, F., Paraninfo, G., Ripamonti, D., Cologni, G., Fabbiani, M., Caputo, S.L., Sighinolfi, L., Ladisa, N., El-Hamad, I., Quiros-Roldan, E., Frank, I.

Volltext

Safety and efficacy of Daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA Foundation cohorts von Rossotti, R., Tavelli, A., Bonora, S., Cingolani, A., Caputo, S.L., Saracino, A., Lapadula, G., Marinaro, L., Uberti-Foppa, C., Mussini, C., Puoti, M., Monforte, A.D.

Volltext

THU-379 - Safety and efficacy of Daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA Foundation cohorts von Rossotti, R., Tavelli, A., Bonora, S., Cingolani, A., Caputo, S.L., Saracino, A., Lapadula, G., Marinaro, L., Uberti-Foppa, C., Mussini, C., Puoti, M., Monforte, A.D.

Volltext

THU-226 - Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy von d 'Arminio Monforte, A., Antinori, A., Cozzi-Lepri, A., Ceccherini-Silberstein, F., Castagna, A., Caputo, S.L., Mussini, C., De Luca, A., Madeddu, G., Cingolani, A., Tavelli, A., Taliani, G., Gori, A., Girardi, E., Puoti, M.

Volltext